- AstraZeneca Evusheld long-acting antibody combination approved in EU for the treatment of COVID-19
- Just 2 Months of Ketogenic Diet Is Enough to Improve Brain Cognitive Function
- Do you still think Pfizer COVID-19 vaccine effective?
- How is the first batch of frozen people after 50 years?
- COVID-19 infection increases risk of a range of neurological diseases,
- Cancer patients eating ice cream can reduce this side effect of chemotherapy
BioNTech: No need to develop a new COVID-19 vaccine against Delta variant. BioNTech claims that its mRNA vaccine can deal with delta mutant strains, and there is no need to develop a new version for the time being.
As the COVID-19 pandemic continues, the COVID-19 virus has accumulated more and more mutations. At present, the World Health Organization (WHO) has marked 11 COVID-19 mutants that need attention, of which the most important is the delta mutant ( Delta). The delta mutant strain was first discovered in India at the end of 2020 and has now become the main strain in most parts of the world.
The delta mutant strain has many new characteristics: it is more adaptable to the human body, spreads faster, has a higher viral load, takes longer to treat, and is more likely to develop into severe illness. Recently, many countries have seen epidemics caused by delta mutant infections, which also allows everyone to see the spreading power of delta mutants.
Some studies have shown that the delta mutant strain has a stronger immune escape ability, and there has been a breakthrough infection that is still infected after vaccination. This has also triggered everyone to wonder whether the current COVID-19 vaccine has sufficient preventive ability against the delta mutant strain. Guess.
On August 9, 2021, Ugur Sahin, CEO of COVID-19 mRNA research and development company BioNTech, stated that the first-generation COVID-19 vaccine developed by BioNTech/Pfizer can effectively deal with COVID-19 mutants including Delta, so there is no need to develop a new version for the time being .
He further explained that the new version needs to be developed only when the vaccine is obviously ineffective or the protection rate is insufficient. The current situation of the epidemic is changing rapidly, and the delta mutant strain currently dominates, but if another variant replaces it, what is now made The decision will soon be proven wrong. Therefore, the appropriate decision must be made at the appropriate time.
At present, it is quite certain that mRNA still has sufficient protective effect on the COVID-19 mutant strain, and the protective effect can be further enhanced by supplementing the strengthening needle. If more mutant strains appear in the next 6-12 months, it will not be too late to develop a new version. It is obviously not the time yet.
At present, many countries and regions have started the COVID-19 vaccine booster plan. For example, France and Germany will start to provide the elderly and other susceptible people with the COVID-19 vaccine booster in September.
BioNTech/Pfizer has already shipped about 1 billion doses of mRNA vaccines to more than 10 countries and regions around the world. It is expected that the production capacity will reach 3 billion doses this year and will increase to 4 billion doses in 2022.
BioNTech: No need to develop a new COVID-19 vaccine against Delta variant
(source:internet, reference only)